CAR - T CD19/CD20/CD22/CD30

Clinical trials for CAR - T CD19/CD20/CD22/CD30 explained in plain language.

Never miss a new study

Get alerted when new CAR - T CD19/CD20/CD22/CD30 trials appear

Sign up with your email to follow new studies for CAR - T CD19/CD20/CD22/CD30, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

Supercharged immune cells take on tough lymphoma

Disease control Completed

This completed Phase 2 trial tested a special type of immune cell therapy called CAR-T in 168 patients with relapsed or refractory non-Hodgkin lymphoma. The CAR-T cells were designed to recognize four different targets on cancer cells (CD19, CD20, CD22, and CD30). Patients receiv…

Matched conditions: CAR - T CD19/CD20/CD22/CD30

Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control

Last updated Jun 27, 2026 13:00 UTC

CAR - T CD19/CD20/CD22/CD30

Get alerted when new CAR - T CD19/CD20/CD22/CD30 trials appear

Supercharged immune cells take on tough lymphoma